Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants
- Conditions
- Amyotrophic Lateral Sclerosis (Healthy Volunteers)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT05795907
- Locations
- 🇺🇸
Prism Research-Site Number:8400001, Saint Paul, Minnesota, United States
A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Amlitelimab DP2Drug: Amlitelimab DP1
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 32
- Registration Number
- NCT05796479
- Locations
- 🇺🇸
Clinical Pharmacology of Miami-Site Number: 8400001, Hialeah, Florida, United States
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 901
- Registration Number
- NCT05769777
- Locations
- 🇧🇷
Centro de Pesquisas da Clínica IBIS- Site Number : 0760002, Salvador, Bahia, Brazil
🇺🇸Alabama Allergy & Asthma Center - Birmingham - Brookwood Boulevard- Site Number : 8400050, Birmingham, Alabama, United States
🇺🇸Research Solutions of Arizona- Site Number : 8400020, Litchfield Park, Arizona, United States
Avalglucosidase Alfa Pregnancy Study
- Conditions
- Pompe DiseasePregnancy
- Interventions
- Biological: avalglucosidase alfa-NGPT (GZ402666) IVBiological: avalglucosidase alfa-NGPT (GZ402666)
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 100
- Registration Number
- NCT05734521
- Locations
- 🇺🇸
Investigational site worldwide, Bridgewater, New Jersey, United States
A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT05731128
- Locations
- 🇿🇦
Investigational Site Number : 7100002, Cape Town, South Africa
🇿🇦Investigational Site Number : 7100007, Cape Town, South Africa
🇿🇦Investigational Site Number : 7100003, Gqeberha, South Africa
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Sanofi
- Registration Number
- NCT05726682
Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above
- Conditions
- Rhinitis Allergic
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 203
- Registration Number
- NCT05720455
A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 26
- Registration Number
- NCT05718258
- Locations
- 🇺🇸
Clinical Pharmacology of Miami Site Number : 8400002, Miami, Florida, United States
🇺🇸Nucleus Network Site Number : 8400001, Saint Paul, Minnesota, United States
🇩🇪Investigational Site Number : 2760001, Kiel, Germany
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukaemia
- Interventions
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 7
- Registration Number
- NCT05712278
- Locations
- 🇺🇸
~MD Anderson Cancer Center Site Number : 8400002, Houston, Texas, United States
🇺🇸University of Nebraska Medical Center Site Number : 8400003, Omaha, Nebraska, United States
🇺🇸Albert Einstein College of Medicine Site Number : 8400001, Bronx, New York, United States
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 74
- Registration Number
- NCT05704049
- Locations
- 🇦🇺
Investigational Site Number : 0360002, Wollongong, New South Wales, Australia
🇧🇷Hospital Mae de Deus Site Number : 0760002, Porto Alegre, Rio Grande Do Sul, Brazil
🇦🇺Investigational Site Number : 0360001, Fitzroy, Victoria, Australia